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Abstract
Background: A disadvantage of prostate-specific antigen (PSA) for the early detection of
prostate cancer (PCa) is that many men must be screened, biopsied, and diagnosed to prevent
one death.
Objective: To increase the speciﬁcity of screening for lethal PCa at an early stage.
Design, setting, and participants: We conducted a case–control study nested within a
population-based cohort. PSA and three additional kallikreins weremeasured in cryopreserved
blood from a population-based cohort in Va¨sterbotten, Sweden. Of 40 379men providing blood
at ages 40, 50, and 60 yr from 1986 to 2009, 12 542 men were followed for >15 yr. From this
cohort, the Swedish Cancer Registry identiﬁed 1423 incident PCa cases, 235 with distant
metastasis.
Outcome measurements and statistical analysis: Risk of distant metastasis for different
PSA levels and a prespeciﬁed statistical model based on the four kallikrein markers.
Results and limitations: Most metastatic cases occurred in men with PSA in the top quartile
at age 50 yr (69%) or 60 yr (74%), whereas 20-yr risk of metastasis for men with PSA below
median was low (0.6%). Among men with PSA >2 ng/ml, a prespeciﬁed model based on four
kallikrein markers signiﬁcantly enhanced the prediction of metastasis compared with PSA
alone. About half of all menwith PSA>2 ng/ml were deﬁned as low risk by this model and had
a 1% 15-yr risk of metastasis.
Conclusions: Screening at ages 50–60 yr should focus on men with PSA in the top quartile. A
marker panel can aid biopsy decision making.
Patient summary: For men in their ﬁfties, screening should focus on those in the top 10% to
25% of PSA values because the majority of subsequent cases of distant metastasis are found
among these men. Testing of four kallikrein markers in men with an elevated PSA could aid
biopsy decision making.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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1. Introduction
Recent evidence from randomized trials provides clear
evidence that screening for prostate cancer (PCa) by testing
serum levels of prostate-specific antigen (PSA) reduces
cancer-specific mortality in men who would not otherwise
be screened [1,2]. However, PSA is not specific to lethal PCa.
As a result, many men need to be screened, biopsied, and
diagnosed to prevent one death. One estimate is that
781 men need to be screened and 27 diagnosed per PCa
death avoided at 13 yr [1].
Oneway to change the harm-to-benefit ratio would be to
screen for cancers that are destined to become lethal.
Metastatic PCa is associated with severe disease morbidity
and a very high risk of PCa-specific death. We tested the
hypothesis that PSA and a panel of PSA-related markers
could predict the long-term risk of metastatic PCa in a large
representative population-based longitudinal study of men
providing cryopreserved blood at ages 40, 50, and 60 yr
from 1986 to 2009.
2. Patients and methods
2.1. Study population
The Va¨sterbotten Intervention Project (VIP) [3] is an ongoing population-
based cohort study initiated in 1986 in which residents of Va¨sterbotten
County, Sweden, are invited to receive a health examination at ages 40,
50, and 60 yr with blood drawn for cryopreservation. By January 2009,
VIP included data on 40 379 unique men with 50 557 blood draws,
representing >57% of the total background population [4]. Initially the
rate of PSA testing in this population was low, but it has increased over
recent years: The proportion of PCa cases for which opportunistic
screening was the cause for work-up leading to diagnosis increased from
9% in 2000 to 26% in 2005 and to 38% in 2011 [5]. However, these recent
changes are likely to have little impact onmetastasis rates in our current
cohort due to the long lead time between diagnosis and metastasis.
2.2. Case identification and outcomes
In January 2009, the VIP cohort was linked to the Northern Sweden
Regional Cancer Registry, part of the Swedish Cancer Registry, using the
Swedish personal identity number. We identiﬁed 1423 incident PCa
cases in the VIP cohort, 1377 of which had cryopreserved blood available
for analysis. Clinical data were retrieved from the National Prostate
Cancer Register. We reviewed hospital medical charts of men diagnosed
with cancer to identify men who later had documented evidence of
metastatic disease (ie, a positive bone scan) during the follow-up period.
There were 126 patients with metastatic PCa diagnosed during follow-
up who subsequently died from PCa, according to the Cause of Death
Registry. Cause of death was assessed by medical chart review or, when
chartswere not available (n = 4), the Swedish Cause of Death Registry. An
additional 12 men who died of PCa but who had not had metastases
diagnosed prior to death were considered to have hadmetastatic disease
at the date of death.
2.3. Control selection
Separate case–control matches were conducted for each end point: PCa
diagnosis, PCa metastases, and PCa-speciﬁc death. There were separate
analyses for men aged 40, 50, and 60 yr at baseline. For each relevant end
point, we randomly selected three controls who were alive and event
free at the date of the pertinent event for the index case, were within
3 mo of age of the index case, and had provided a blood sample within
3 mo of the blood draw for the index case. For the end point of PCa-
speciﬁc death, all cases were matched successfully to three controls; for
PCa metastases and PCa diagnosis, we expanded the window in 1-mo
increments to 12 mo until three controls were identiﬁed.
All participants gave written informed consent at the time of
recruitment, and the project was approved by the research ethics board
at Umea˚ University (research authorization number 2009-1436-31).
2.4. Laboratory methods
We measured four kallikrein (KLK) markers—human kallikrein-related
peptidase 2 (hK2) and total, free, and intact PSA—in cryopreserved blood
samples from cases and controls. All laboratory analyses were conducted
blind to outcome and case–control status. We measured total and free
PSA with the dual-label DELFIA ProStatus assay (PerkinElmer, Turku,
Finland) [6], calibrated against the World Health Organization (WHO)
96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards, in
previously unthawed cryopreserved heparin anticoagulated blood
plasma. Intact PSA and hK2 were measured using F(ab0)2 fragments
of the monoclonal capture antibodies to reduce the frequency of
nonspeciﬁc assay interference [7].
2.5. Statistical methods
To estimate absolute risk, we used predictive mean matching to impute
marker levels for men not selected as controls and for 16 men (1 man
aged 50 yr and 15 men aged 60 yr) with metastasis who had missing
samples. Statistical analyses were performed on the population level
utilizing the measured and imputed values combined across 10 imputa-
tions using the Rubin rules. The four KLK markers were combined as
previously described [8] into a statistical risk predictionmodel that gives
Table 1 – Participant characteristics in the Va¨sterbotten
Intervention Project*
Age 40 yry
(n = 17 086)
Age 50 yry
(n = 17 837)
Age 60 yry
(n = 15 634)
PSA, ng/ml, at
ages 40, 50,
and 60 yr
Median (25th, 75th percentile)
Subsequent
prostate cancer
diagnosis
n = 77z
1.3 (0.9, 2.1)
n = 399z
2.0 (1.3, 3.3)
n = 947z
3.6 (2.0, 6.0)
Subsequent distant
metastasis
n = 10z
1.1 (0.7, 3.1)
n = 52z
1.7 (1.2, 3.4)
n = 173z
4.5 (2.1, 9.8)
Controls with PSA
measurement
n = 228
0.7 (0.5, 0.9)
n = 1157
0.8 (0.6, 1.2)
n = 2598
1.1 (0.7, 2.0)
Controls with
imputed PSA
measurement
n = 16 781
0.7 (0.5, 0.9)
n = 16 [1_TD$DIFF]281
0.8 (0.6, 1.2)
n = 12 089
1.1 (0.7, 2.0)
No. of men
Men at risk§
10 yr 9172 9100 6725
15 yr 5115 4339 3088
20 yr 1117 645 422
PSA = prostate-speciﬁc antigen.
* A total of 12 men died from prostate cancer without documented
metastasis. These were recorded as having metastasis on the date of death.
y Age at baseline showing the number of men providing blood samples.
z Number of men providing blood at ages 40, 50, and 60 yr later diagnosed
with prostate cancer and with documented evidence of distant metastases.
§ Number of men providing blood at ages 40, 50, and 60 followed for 10, 15,
and 20 yr.
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the risk of any grade (or Gleason score 7) cancer at prostate biopsy.
However, because the current study used anticoagulated blood plasma
rather than serum, the model was adjusted using biopsy data from the
UK Prostate Testing for Cancer and Treatment (ProtecT) study [9] that
used blood plasma samples anticoagulated with ethylenediaminete-
traacetic acid to predict Gleason score7 (high-grade) cancer at 10-core
prostate biopsy. The model was completed before it was applied to the
VIP cohort [10], making the current study an external validation of a
prespeciﬁed model. All analyses were conducted in Stata v.12 software
(StataCorp, College Station, TX, USA).
3. Results
Table 1 shows the number of men in the VIP cohort who
were aged 40, 50, and 60 yr at the time of the blood draw
and PSA concentrations at those ages in men subsequently
diagnosedwith PCa and inmenwith documented evidence
of distant metastases and their matched controls. It also
shows the number of living men at risk of a PCa diagnosis or
metastatic PCa at different durations of follow-up and the
number ofmenwith documentedmetastases. TheVIP cohort
included 12 542 men followed for >15 yr, 1423 men
diagnosed with incident PCa, and 235 cases with documen-
ted evidence of distant PCametastasis. Details on patient and
tumor characteristics (including PSA level at time of
diagnosis) are described in Supplementary Table 1. PSA
concentrations at ages 40, 50, and 60 yr in controls were
similar to previous population estimates in Sweden [11,12],
Ireland [13], and the United States [14–16].
There were very few metastatic cases (n = 10) in men
aged 40 yr at blood collection; further analyses are not
presented in the primary text of this paper (Supplementary
Table 2). For the older cohorts, as shown in Figure 1 and
Table 2, there was a strong association between 15- to 20-yr
risk of metastases and PSA, with a C-index of 0.816 (95%
confidence interval [CI], 0.718–0.889) for PSA at age 50 and
[(Fig._1)TD$FIG]
Fig. 1 – Risk of distant metastasis within 15 yr (dashed line) and 20 yr
(solid line) by prostate-specific antigen (PSA). The four areas depicted in
dark and light orange reflect the four quartiles of the population
distribution of PSA levels. (A) Age 60 yr; (B) age 50 yr.
PSA = prostate-specific antigen.
Table 2 – Risk of distant prostate cancer metastases by 15 and 20 yr of follow-up
PSA level, ng/ml Absolute risk of metastases (95% CI) Cumulative proportion of
metastases,* % (95% CI)
15-yr risk 20-yr risk
Age 50 yr
Top decile >1.9 2.40 (1.47–3.70) 3.15 (1.94–4.82) 48 (34–61)
Top quartile >1.3 1.48 (0.99–2.12) 2.14 (1.40–3.14) 69 (57–82)
Second quartile 0.8–1.3 0.25 (0.08–0.67) 0.89 (0.33–2.03) 85 (75–95)
Third quartile 0.6–0.8 0.13 (0.02–0.54) 0.56 (0.12–1.89) 92 (85–100)
Bottom quartile <0.6 0.15 (0.03–0.47) 0.48 (0.07–1.98) 100
Below 63rd centile <1.0 0.14 (0.05–0.31) 0.55 (0.23–1.17)
Below median <0.8 0.14 (0.05–0.35) 0.53 (0.18–1.34) –
Overall 0.52 (0.37–0.72) 1.06 (0.72–1.51) –
Age 60 yr
Top decile >3.8 9.33 (7.26–11.71) 14.29 (10.73–18.35) 56 (48–64)
Top quartile >2.1 5.28 (4.25–6.46) 8.84 (6.97–10.99) 74 (67–81)
Second quartile 1.2–2.1 1.55 (0.95–2.41) 2.56 (1.53–4.02) 91 (86–95)
Third quartile 0.7–1.2 0.59 (0.27–1.18) 0.76 (0.34–1.52) 97 (95–100)
Bottom quartile <0.7 0.26 (0.07–0.81) 0.48 (0.12–1.39) 100
Below median <1.2 0.44 (0.23–0.79) 0.63 (0.32–1.14) –
Below 41st centile <1.0 0.43 (0.21–0.83) 0.56 (0.26–1.10)
Overall 2.00 (1.66–2.39) 3.31 (2.71–4.00) –
PSA = prostate-speciﬁc antigen.
* Cumulative proportions are given by cumulative quantile. For example, 85% of documented metastases occurred in men who had PSA in the top or second
quartile at age 50 yr; 56% of metastases occurred in men in the top decile of PSA levels at age 60 yr.
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0.847 (95% CI, 0.807–0.886) for PSA at age 60 (Supplemen-
tary Table 3).Most caseswithmetastasis were found among
men whose PSA was above median for a decade or more
before metastases were diagnosed (Supplementary Fig. 1;
Supplementary Table 4). PSA measured at age 50 or
60 provided a wide separation of risk, with a 4- to 14-
fold higher relative risk of metastases in men with PSA
concentrations in the top quartile compared with those
below the median (Table 2). As shown in Table 2, 69% of
metastatic cases were documented in men with PSA in the
top quartile at age 50 (>1.3 ng/ml); 74% of metastatic cases
were documented inmenwith PSA in the top quartile at age
60 (>2.1 ng/ml). However, PSA levels below the median at
ages 50–60 yr were associated with a very low risk of
distant metastases. The 20-yr risk of metastasis for men
with PSA 1.0 ng/ml at age 60 (close to the median) was
<0.6% (Table 2). Despite the substantially elevated long-
term risk of distant metastases associated with a PSA
concentration in the top quartile or decile at age 50 or 60,
the vast majority of these men remained metastasis free at
15–20 yr (Fig. 1; Supplementary Table 2 and 4).
We then examined whether a prespecified statistical
model based on four KLK markers measured in the ProtecT
study participants and developed to predict the risk of
high-grade cancer at prostate biopsy [10] also could predict
distant metastasis occurring 10–20 yr later (Supplementary
Table 3). Although themodel did not enhance discrimination
of PSA in allmen, it did so inmenwith PSA above themedian
at age 50 or 60. For instance, amongmenwith PSA>2 ng/ml
at age 50, discrimination was 0.751 for total PSA alone
comparedwith0.863 for themodel (increaseof0.112;95%CI,
0.020–0.219); for men with PSA >2 ng/ml at age 60,
discrimination increased from 0.805 to 0.875 (0.070; 95%
CI, 0.040–0.097).
Given these results, we conducted a decision analysis
evaluating the hypothetical clinical outcomes had the KLK
marker–based model data been used to aid decisions
about biopsy in the VIP cohort. Biopsying all men with PSA
3.0 ng/ml, the approach used in the randomized trial
supporting PSA screening [1,2] would have resulted in a
biopsyperformedon15.6%ofmenaged60yr.This ratewould
have been reduced by 38% (Fig. 2A) if biopsy was
recommended only to those with 7.5% risk of high-grade
cancer according to the model (Table 3; Supplementary
Table 5). Among men aged 60 yr with PSA 3 ng/ml and
<7.5% risk according to the model, the 15-yr risk of distant
metastases remained low (0.99%) compared with the
population average (2%). For men with PSA 2 ng/ml at
age 50 (top decile of PSA levels at age 50), using 5% risk
according to themodel as the criterion for biopsywould lead
to only 41% of these men undergoing a biopsy (Fig. 2B).
Amongallmenaged50yrwithPSA2ng/ml, thosewith<5%
risk according to themodel had a very low 15-yr risk (0.5%)
of distantmetastasis (Table 3). Thus a substantial proportion
of menwith modestly increased PSA but low KLK risk scores
identified by our screening strategy would be excluded
frombiopsy, and for thesemen, there is little risk ofmissing a
lethal cancer even in the absence of frequent (e.g. biennial)
follow-up.
4. Discussion
In this large representative cohort from Sweden, with
>12 500 men followed for >15 yr and initially low rates of
opportunistic PSA testing, PSA measured in cryopreserved
blood collected at age 50 or 60 predicted metastasis at
15- to 20-yr follow-up. In the subset of men with modestly
elevated PSA, a prespecified model based on a panel of four
KLK markers increased the predictive discrimination of
metastasis.
Risk stratification contributed by PSA was far greater
than that reported for other risk factors such as race or
family history [17]. Among men with modestly elevated
PSA at age 50 or 60, the four KLK panel yielded C-indexes
from 0.82 to 0.88 for the prediction of documented distant
metastasis. This can be compared with discrimination close
[(Fig._2)TD$FIG]
Fig. 2 – Risk of distant metastasis among men with elevated prostate-
specific antigen (PSA) by four kallikrein (KLK) panel score. (A) Age 60 yr
and PSA I3 ng/ml (n = 2432). Green line: overall risk of distant
metastasis; orange line: risk of distant metastasis among men with four
KLK panel score I7.5% (62% of the men); blue line: risk of distant
metastasis among men with four KLK panel score <7.5% (38% of the
men). (B) Age 50 yr and PSA I2 ng/ml (n = 1692). Green line: overall risk
of distant metastasis; orange line: risk of distant metastasis among men
with four KLK panel score I5% (41% of the men); blue line: risk of
distant metastasis among men with four KLK panel score <5% (59% of
the men).
PSA = prostate-specific antigen.
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to 0.60 for the Gailmodel that is used clinically to determine
eligibility for breast cancer chemoprevention [18].
Several long-term studies including a prospective
observational study reported by Parkes et al [19] and
others reviewed by Loeb et al [16] have found PSA to be
highly prognostic of the long-term risk of aggressive PCa in
unscreened men. The Malmo¨ Preventive Project (MPP)
[11,12] that involved blood samples taken from 1974 to
1986 with follow-up for metastasis and death through
2006 is most comparable with the current study. Although
overall estimates of PCa risk are very similar between the
two studies, the C-index of PSA for metastasis was
somewhat lower in the current study: 0.86 at 25 yr in
MPP versus 0.85within<20 yr in VIP. Thismay be related to
the advent of opportunistic PSA testing in Sweden. Some
men with elevated PSA at age 60 destined to develop
metastases would have their cancer detected early by PSA
testing and be cured by early treatment.
Our results also replicated prior findings that the KLK
markers measured in blood enhance the discrimination of
malignant from benign PSA elevations [8,20]. Enormous
efforts have been invested searching for biomarkers to be
used with PSA to improve screening for PCa [21–25].
Although some markers are predictive of biopsy outcome,
this is the first time markers have been shown to improve
long-termprediction of distantmetastasis, in this casewith
large increases in discrimination. These findings support
the use of the KLK panel as a reflex test for biopsy inmidlife
among men with a modestly elevated PSA. For instance,
compared with biopsying all men with PSA 3 ng/ml,
biopsying men with PSA 2 ng/ml and 10% risk from the
panelwould reduce biopsy rates by 45%but detect a similar
number of men who would develop distant metastases
within 10 yr (56 vs 57 per 10 000men). Menwith amodest
PSA elevation but a low risk of high-grade cancer according
to the panel could be exempted from biopsy and reassured
that they would be unlikely to develop metastatic disease,
even if PSA and the other KLKmarkers were not monitored
every year.
Our findings strongly support a risk-stratified approach
to screening and biopsy. In men aged 50 yr, the 15-yr risk of
metastasis among those in the top decile for PSA was 3.15%,
sixfold higher than men with PSA below the median. The
concentration of high-risk disease in this age group, with
48% ofmetastatic cases occurring in themenwith PSA levels
in the highest 10%, suggests that screening should focus on
those men. In contrast, we were unable to identify a
subgroup of men aged 40 yr at a substantially increased risk
of distant metastasis within 15 yr, making it difficult to
justify screening in this age group. The identification of a
small subset ofmenwith elevated PSA at ages 50–60 yrwith
a substantially increased risk of developing metastatic
disease many years later has important implications for the
development of novel preventive strategies. Use of the KLK
markers as a reflex test may further refine stratification of
risk.
The very low long-term risk for PCa [26,27] and
metastases [11] in men with PSA <1 ng/ml was observed
Table 3 – Risk of distant metastasis by prostate-specific antigen and kallikrein risk*
PSA group n (%) 10 yr (95% CI) 15 yr (95% CI) 20 yr (95% CI) Metastases
by 10 yr per
10 000 men
Metastases
by 20 yr per
10 000 men
Age 50
PSA 0 ng/ml 17 837 0.09 (0.05–0.17) 0.52 (0.37–0.72) 1.06 (0.72–1.51) 9 106
PSA 2 ng/ml 1692 0.67 (0.30–1.36) 2.41 (1.46–3.73) 3.20 (1.96–4.93) 6 30
KLK risk 5% 696 (41) 1.37 (0.56–2.88) 4.97 (2.91–7.83) 6.80 (3.99–10.61) 5 27
<5% 996 (59) 0.18 (0.01–1.24) 0.49 (0.07–2.06) 0.49 (0.07–2.06) 1 3
KLK risk 7.5% 318 (19) 2.40 (0.88–5.31) 8.25 (4.41–13.62) 10.68 (5.74–17.38) 4 19
<7.5% 1374 (81) 0.26 (0.04–1.03) 0.90 (0.34–2.04) 1.25 (0.47–2.79) 2 11
KLK risk 10% 189 (11) 4.01 (1.41–8.83) 10.67 (5.10–18.58) 10.67 (5.10–18.58) 4 11
<10% 1502 (89) 0.23 (0.04–0.93) 1.26 (0.58–2.45) 2.17 (1.06–3.98) 2 19
PSA 3 ng/ml 549 1.51 (0.56–3.36) 4.66 (2.45–7.92) 6.13 (3.25–10.26) 5 19
Age 60
PSA 0 ng/ml 15 634 0.88 (0.70–1.08) 2.00 (1.66–2.39) 3.31 (2.71–4.00) 88 331
PSA 2 ng/ml 4318 2.42 (1.89–3.06) 5.04 (4.06–6.17) 8.47 (6.69–10.50) 67 234
KLK risk 5% 3104 (72) 3.27 (2.54–4.13) 6.77 (5.44–8.29) 11.04 (8.71–13.69) 65 219
<5% 1214 (28) 0.19 (0.01–1.28) 0.38 (0.06–1.50) 1.42 (0.19–5.52) 2 15
KLK risk 7.5% 2005 (46) 4.81 (3.72–6.09) 9.05 (7.21–11.16) 14.17 (11.02–17.72) 62 182
<7.5% 2313 (54) 0.25 (0.06–0.76) 1.31 (0.64–2.44) 3.00 (1.48–5.40) 5 52
KLK risk 10% 1337 (31) 6.65 (5.09–8.47) 11.99 (9.45–14.86) 18.88 (14.51–23.69) 57 161
<10% 2982 (69) 0.42 (0.18–0.87) 1.70 (0.99–2.73) 3.22 (1.89–5.12) 10 73
PSA 3 ng/ml 2432 3.63 (2.77–4.65) 6.65 (5.22–8.29) 11.30 (8.65–14.35) 56 176
KLK risk 5% 1954 (80) 4.49 (3.43–5.74) 8.08 (6.34–10.08) 13.73 (10.50–17.38) 56 172
<5% 478 (20) 0 (NA) 0.48 (0.02–3.36) 0.48 (0.02–3.36) 0 4
KLK risk 7.5% 1510 (62) 5.62 (4.29–7.20) 9.85 (7.69–12.32) 16.36 (12.44–20.74) 54 158
<7.5% 922 (38) 0.18 (0.01–1.30) 0.99 (0.28–2.64) 1.82 (0.47–4.99) 2 18
KLK risk 10% 1180 (49) 7.01 (5.34–8.99) 12.35 (9.62–15.43) 19.88 (15.10–25.15) 53 150
<10% 1252 (51) 0.23 (0.04–0.94) 0.82 (0.27–2.01) 1.95 (0.64–4.66) 3 26
CI = conﬁdence interval; KLK = kallikrein; PSA = prostate-speciﬁc antigen.
* A previously developed model to predict risk of Gleason score 7 (high-grade) prostate cancer at biopsy based on a panel of four KLK markers measured in the
blood.
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in earlier studies. Our findings are consistent with prior
research demonstrating that men with a low PSA at age
60 have no mortality reduction from PSA screening but are
at considerable risk of overdiagnosis [28]. This supports the
calls to limit screening in such men.
5. Conclusions
We found that blood levels of PSA at ages 50 and 60 yr are
prognostic of the long-term risk ofmetastatic PCa and that a
panel of KLK markers is strongly predictive of distant
metastasis documented many years later in men with a
modestly elevated PSA. Our study has the following clinical
implications. First, widespread PSA testing at age 40 cannot
be justified. Second, screening can stop in men with PSA
below the median (<1 ng/ml) at age 60 yr. Third, for men
in their fifties, screening could focus mainly on those in the
top decile of PSA (>1.9 ng/ml) because close to half of the
subsequent cases of distant metastasis are found in this
group; men with lower PSAs should still be screened but
less intensively. Finally, four KLK markers measured in the
blood can be used as a reflex test to aid biopsy decisions.
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